Trial Profile
Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 15 Nov 2023 Status changed from active, no longer recruiting to completed.
- 27 Jun 2023 Planned End Date changed from 30 Jun 2024 to 3 Aug 2023.
- 27 Jun 2023 Planned primary completion date changed from 30 Jun 2024 to 3 Aug 2023.